Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory larg...
Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA
Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large B-cell lymphoma ( Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA )
13 Dec 2021
EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free ...
Prof Francois-Xavier Mahon - University of Bordeaux, Bordeaux, France
EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free survival 3 years after TKIs ( Prof Francois-Xavier Mahon - University of Bordeaux, Bordeaux, France )
13 Dec 2021
Real world data supports ciltacabtagene autoleucel as effective option for tripl...
Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Sp...
Real world data supports ciltacabtagene autoleucel as effective option for triple-class exposed r/r MM ( Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Spain )
12 Dec 2021
Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with...
Dr Martin Kaiser - The Institute of Cancer Research, London UK
Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM ( Dr Martin Kaiser - The Institute of Cancer Research, London  UK )
12 Dec 2021
Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted cons...
Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA
Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted consolidation therapy gives highest rate of MRD negativity in NDMM ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )
12 Dec 2021
Latest in combination therapy for NDMM patients
Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA
Latest in combination therapy for NDMM patients ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )
12 Dec 2021
Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail pa...
Dr Guido Gini - Università Politecnica delle Marche, Ancona, Italy
Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail patients with diffuse large B-cell lymphoma. ( Dr Guido Gini - Università Politecnica delle Marche, Ancona, Italy )
11 Dec 2021
Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neop...
Dr Chi-Joan How - Brigham and Women's Hospital, Boston, USA
Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients ( Dr Chi-Joan How - Brigham and Women's Hospital, Boston, USA )
11 Dec 2021
Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in ...
Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in pts with relapsed/refractory B-cell malignancies ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
11 Dec 2021
Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma
Prof Ryan Lynch - University of Washington School of Medicine, Seattle, USA
Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma ( Prof Ryan Lynch - University of Washington School of Medicine, Seattle, USA )
11 Dec 2021
ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high-...
Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston...
ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL) ( Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston, USA )
11 Dec 2021
Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL
Prof Brian Hill - Cleveland Clinic, Cleveland, USA
Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL ( Prof Brian Hill - Cleveland Clinic, Cleveland, USA )
11 Dec 2021